Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp151 | Pituitary - Clinical | ECE2016

Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial

Fleseriu Maria , Melmed Shlomo , Mangal Brian , Strasburger Christian J , Biermasz Nienke R

Introduction: Although biochemical markers of acromegaly disease activity, including GH and IGF1, may fluctuate from day-to-day, biochemical treatment response in clinical trials is generally monitored using single-point analyses. Accordingly, longitudinal evaluations may assess patient status more accurately. In a phase 3 trial, oral octreotide capsules (OOC) demonstrated sustained composite endpoint GH and IGF1 response for ≤13 months in 151 patients with acromegaly pr...

ea0020p545 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Pre-treatment IGF-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease

Biermasz Nienke R , Wassenaar Moniek J E , van der Klaauw Agatha A , Pereira Alberto M , Smit Johannes W A , Roelfsema Ferdinand , Wolterbeek Ron , Kroon Herman M , Kloppenburg Margreet , Romijn Johannes A

Objective: To identify factors influencing the development of osteoarthritis during long-term control of acromegaly, focusing on disease specific parameters, growth hormone (GH) and insulin-like growth factor I (IGF-I) concentrations and duration of disease, adjusted for the well-known determinants of primary osteoarthritis.Design: Follow-up study.Methods: We studied 67 patients, with adequate biochemical control of acromegaly for ...

ea0056gp202 | Pituitary Clinical | ECE2018

Endoscopic vs microscopic transsphenoidal surgery for Cushing’s disease: a systematic review and meta-analysis

Broersen Leonie H A , Biermasz Nienke R , van Furth Wouter R , de Vries Friso , Verstegen Marco J T , Dekkers Olaf M , Pereira Alberto M

Background: Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, resulting in glucocorticoid excess. First-choice treatment is transsphenoidal pituitary surgery, using either a microscopic or endoscopic technique. Convincing evidence supporting the choice for one of both techniques, either based on treatment results or complication rate, is lacking.Objective: We aimed to compare endoscopic and microscopic...

ea0073aep537 | Pituitary and Neuroendocrinology | ECE2021

The perspective of patients with pituitary disease on work according to the expanded ICF model: A qualitative study

Merel Van der Meulen , Lobatto Daniel J. , Wouter R. van Furth , Huisman Sasja D. , Heerkens Yvonne F. , Thea P.M. Vliet Vlieland , Biermasz Nienke R. , Andela Cornelie D.

PurposeAs the majority of patients with pituitary disease are of working age, their health situation may negatively impact their functioning at work. However, work participation can also be influenced by contextual (environmental and personal) factors. The aim of this qualitative study was to investigate the perspective of patients with pituitary disease on their functioning at work and on contextual factors contributing to work-related problems, using t...

ea0020p552 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

The D3 GH receptor polymorphism is associated with osteoarthritis, especially of the hip, in patients with long-term cured acromegaly

Wassenaar Moniek JE , Biermasz Nienke R , van der Klaauw Agatha A , Smit Johannes WA , Pereira Alberto M , Roelfsema Ferdinand , van der Straaten Tahar , Kroon Herman M , Kloppenburg Margreet , Guchelaar HJ , Romijn Johannes A

Objective: To evaluate the impact of the genomic deletion of exon 3 in the growth hormone receptor (d3GHR) on co-morbidities of acromegaly in a well-characterized cohort of patients with long-term remission of acromegaly.Design: Cross sectional study.Methods: The presence of the d3GHR polymorphism was assessed in 86 acromegalic patients and related to clinical outcome, i.e. anthropometric parameters, osteoarthritis, and the metabol...

ea0050p269 | Neuroendocrinology and Pituitary | SFEBES2017

Male IGSF1 deficient humans and mice exhibit somatotroph neurosecretory hyperfunction

Joustra Sjoerd D , Roelfsema Ferdinand , Endert Erik , van Trotsenburg ASPaul , Fliers Eric , Schneider Harald J , Kosilek Robert P , Kroon Herman M , Logan John , Turgeon Marc-Olivier , Zhou Xiang , Toufaily Chirine , Koulouri Olympia , Gurnell Mark , Bassett JHDuncan , Williams Graham R , Oostdijk Wilma , Wit Jan-Maarten , Pereira Alberto M , Biermasz Nienke R , Bernard Dan J , Schoenmakers Nadia

X-linked IGSF1 (immunoglobulin superfamily, member 1) loss-of-function mutations in males are associated with central hypothyroidism, macroorchidism, and a variable spectrum of anterior pituitary dysfunction. Igsf1 deficient male mice also exhibit central hypothyroidism, however, the physiological and molecular function of IGSF1 in both species has not yet been elucidated. Although partial transient GH deficiency is a ra...

ea0050p269 | Neuroendocrinology and Pituitary | SFEBES2017

Male IGSF1 deficient humans and mice exhibit somatotroph neurosecretory hyperfunction

Joustra Sjoerd D , Roelfsema Ferdinand , Endert Erik , van Trotsenburg ASPaul , Fliers Eric , Schneider Harald J , Kosilek Robert P , Kroon Herman M , Logan John , Turgeon Marc-Olivier , Zhou Xiang , Toufaily Chirine , Koulouri Olympia , Gurnell Mark , Bassett JHDuncan , Williams Graham R , Oostdijk Wilma , Wit Jan-Maarten , Pereira Alberto M , Biermasz Nienke R , Bernard Dan J , Schoenmakers Nadia

X-linked IGSF1 (immunoglobulin superfamily, member 1) loss-of-function mutations in males are associated with central hypothyroidism, macroorchidism, and a variable spectrum of anterior pituitary dysfunction. Igsf1 deficient male mice also exhibit central hypothyroidism, however, the physiological and molecular function of IGSF1 in both species has not yet been elucidated. Although partial transient GH deficiency is a ra...

ea0073oc14.5 | Oral Communications 14: Across Endocrinology | ECE2021

The use of e-REC for capturing the occurrence of covid-19 infections in people with rare endocrine conditions

Bryce Jillian , Guisto Victoria di , Ali Salma Rashid , Alexandraki Kristi , Biermasz Nienke R , Brandi Maria Luisa , Castinetti Frederic , Druce Maralyn , Fugazzola Laura , Johannsson Gudmundur , Karavitaki Niki , Luger Anton , Marazuela Monica , Paschou Stavroula , Persani Luca , Puig-Domingo Manel , Reisch Nicole , Schalin-Jantti Camilla , Young Jacques , Appelman-Dijkstra Natasha M , Grozinsky-Glasberg Simona , Pereira Alberto M , Ahmed S. Faisal

IntroductionFollowing the onset of the COVID-19 pandemic in early spring 2020, there was a need to identify the burden of this infection on people with rare endocrine conditions. The European Registries For Rare Endocrine Conditions (EuRRECa) was launched in 2018 in collaboration with Endo-ERN, ESPE and ESE to support the needs of the wider endocrine community. The project consists of an e-reporting (e-REC) platform that allows monthly reporting of new c...